Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/326814

Lähdeviite

Paldanius , P M 2020 , ' Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation ' , Diabetes & metabolism journal , vol. 44 , no. 6 , pp. 785-801 . https://doi.org/10.4093/dmj.2020.0179

Julkaisun nimi: Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
Tekijä: Paldanius, Päivi Maria
Tekijän organisaatio: HUS Children and Adolescents
Clinicum
Children's Hospital
Helsinki University Hospital Area
CAMM - Research Program for Clinical and Molecular Metabolism
Research Programs Unit
University of Helsinki
Päiväys: 2020-12
Kieli: eng
Sivumäärä: 15
Kuuluu julkaisusarjaan: Diabetes & metabolism journal
ISSN: 2233-6079
DOI-tunniste: https://doi.org/10.4093/dmj.2020.0179
URI: http://hdl.handle.net/10138/326814
Tiivistelmä: Type 2 diabetes mellitus (T2DM) is a complex and progressive chronic disease characterised by elevating hyperglycaemia and as-sociated need to gradually intensify therapy in order to achieve and maintain glycaemic control. Treating hyperglycaemia with se-quential therapy is proposed to allow holistic assessment of the efficacy and risk-to-benefit ratio of each added component. How-ever, there is an array of evidence supporting the scientific rationale for using synergistic, earlier, modern drug combinations to achieve glycaemic goals, delay the deterioration of glycaemic control, and, therefore, potentially preserve or slow down the declin-ing β-cell function. Additionally, implementation of early combination(s) may lead to opportunities to combat clinical inertia and other hurdles to optimised disease management outcomes. This review aims to discuss the latest empirical evidence for long-term clinical benefits of this novel strategy of early combination in people with newly diagnosed T2DM versus the current widely-im-plemented treatment paradigm, which focuses on control of hyperglycaemia using lifestyle interventions followed by sequentially intensified (mostly metformin-based) monotherapy. The recent reported Vildagliptin Efficacy in combination with metfoRmin For earlY treatment of T2DM (VERIFY) study results have provided significant new evidence confirming long-term glycaemic durability and tolerability of a specific early combination in the management of newly diagnosed, treatment-naïve patients world-wide. These results have also contributed to changes in clinical treatment guidelines and standards of care while clinical imple-mentation and individualised treatment decisions based on VERIFY results might face barriers beyond the existing scientific evi-dence.
Avainsanat: 3121 General medicine, internal medicine and other clinical medicine
BETA-CELL FUNCTION
TYPE-2 DIABETES-MELLITUS
METFORMIN-TREATED PATIENTS
INTENSIVE INSULIN THERAPY
BLOOD-GLUCOSE CONTROL
DRUG-NAIVE PATIENTS
INITIAL COMBINATION
CLINICAL INERTIA
GLYCEMIC CONTROL
BASAL INSULIN
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by_nc
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
dmj_2020_0179.pdf 347.1KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot